Clinical trials · Washington, D.C., DC
Proteinuria clinical trials in Washington, D.C.
We’re tracking 3 recruiting proteinuria studies with a site in or near Washington, D.C. — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05457283RecruitingPhase 3
Finerenone safety study for children with kidney disease
This trial studies how safely finerenone works over 18 months in children and young adults with chronic kidney disease who also take an ACE inhibitor or ARB. It aims to better understand long-term side effects when used together with standard kidney blood-pressure medicines.
Washington D.C., District of ColumbiaAges 1–18 - NCT05196035RecruitingPhase 3
Finerenone plus blood-pressure medicine for kids with kidney disease
This Phase 3 study tests whether finerenone works and is safe in children with chronic kidney disease and significant protein in the urine, when taken with an ACE inhibitor or ARB. It also studies how the medicine moves through the body and its effects over time.
Washington D.C., District of ColumbiaAges 6 months–17 years - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90
Hear when a new Proteinuria trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Proteinuria trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting proteinuria studies listed above.
- Children's National Medical Center · 2 studies
- The Charlotte R. Bloomberg Children's Center · 2 studies
- National Institutes of Health Clinical Center
- National Naval Medical Center
What taking part in a proteinuria study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there proteinuria clinical trials near Washington, D.C.?
- Yes. We're currently tracking 3 recruiting proteinuria studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a proteinuria study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a proteinuria trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New proteinuria studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.